Live Breaking News & Updates on Prnewswire Epicentrx

Stay updated with breaking news from Prnewswire epicentrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting

/PRNewswire/ EpicentRx, a clinical-stage biopharmaceutical company, announced that The American Society of Clinical Oncology (ASCO) has invited Dr. Anthony. ....

United States , Prnewswire Epicentrx , Lucyb Kennedy , Anthonyp Conley , Saar Yaniv , Ashley Thomaz , Business Development Contact , American Society Of Clinical Oncology , Md Anderson Cancer Center , Epicentrx Inc , American Society , Clinical Oncology , Cancer Center , Sarcoma Specialist , Oral Abstract Session , Developmental Therapeutics , Development Contact ,

Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo® [nivolumab] in Traditionally Checkpoint Inhibitor Non-Responsive Tumors

/PRNewswire/ EpicentRx, a leading edge, clinical stage biopharmaceutical company, announced publication of results in the well-respected, international. ....

Prnewswire Epicentrx , Tony Reid ,

EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers

/PRNewswire/ EpicentRx, a leading edge, clinical stage biopharmaceutical company, announced the publication of Phase 2 results of the PREVLAR trial which. ....

United States , University Of Texas , Prnewswire Epicentrx , David Sher , Stephen Sonis , Faculty Of The Dana Farber Cancer Institute , University Of Texas Southwestern , International Journal Of Radiation Oncology , International Journal , Radiation Oncology , Texas Southwestern , Harvard Professor , Oral Medicine , Distinguished Faculty , Dana Farber Cancer Institute ,

EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers

/PRNewswire/ EpicentRx, a leading edge, clinical stage biopharmaceutical company, announced the publication of Phase 2 results of the PREVLAR trial which. ....

United States , University Of Texas , Prnewswire Epicentrx , David Sher , Stephen Sonis , Faculty Of The Dana Farber Cancer Institute , University Of Texas Southwestern , International Journal Of Radiation Oncology , International Journal , Radiation Oncology , Texas Southwestern , Harvard Professor , Oral Medicine , Distinguished Faculty , Dana Farber Cancer Institute ,

EpicentRx Announces Presentations Focusing on RRx-001 Inhibition of the NLRP3 Inflammasome at Two Upcoming Scientific Conferences

/PRNewswire/ EpicentRx, a late clinical stage biopharmaceutical company with novel therapies to target cancer and inflammatory diseases, announced it will. ....

United States , San Diego , Prnewswire Epicentrx , Epicentrx Cy , Inflammasome Therapeutics Summit , Control Number , Disease Molecular , Protects Against Inflammasome Driven , Proof Of Concept Trials , Various Disease Groups , Clinical Relevance ,